TIDMPRTC
PureTech Health PLC
05 December 2019
5 December 2019
PureTech Health plc
PureTech Affiliate Vedanta Biosciences Awarded $5.8 Million
CARB-X Grant to Accelerate Development of VE707 for Multi-Drug
Resistant Infections
PureTech Health plc (LSE: PRTC) ("PureTech"), a clinical stage
biotechnology company dedicated to discovering, developing and
commercialising highly differentiated medicines for devastating
diseases, is pleased to note that its affiliate, Vedanta
Biosciences, has been awarded a $5.8 million grant for its VE707
programme targeting multi-drug resistant infections. The grant was
awarded by Combating Antibiotic-Resistant Bacteria
Biopharmaceutical Accelerator (CARB-X), a global non-profit
partnership dedicated to accelerating early development in
antibacterial R&D to address the rising global threat of
drug-resistant bacteria. Vedanta Biosciences is eligible for $3.5
million in further funding upon completion of specific
milestones.
Bharatt Chowrira, JD, PhD, president and chief of business and
strategy at PureTech said: "Increasingly the human microbiome is
being colonised by dangerous bacteria and other microorganisms that
have developed resistance to antimicrobial drugs, mainly through
poor global stewardship of antibiotics. This grant from CARB-X
recognises Vedanta's unique platform and advanced understanding of
the human gut microbiome for developing live biotherapeutic
products with the potential to modulate the intestinal microbiome
to address a range of significant human diseases and health issues,
including drug-resistant pathogens."
The full text of the announcement from Vedanta Biosciences is as
follows:
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to
Accelerate Development of VE707 for Multi-Drug Resistant
Infections
Vedanta Biosciences eligible for an additional $3.5 million upon
completion of certain milestones
Programme addresses significant unmet therapeutic need for major
hospital-acquired infections caused by multi-drug resistant
organisms
CAMBRIDGE, Mass., December 5, 2019 - Vedanta Biosciences, a
clinical-stage biopharmaceutical company developing a new category
of therapies for immune-mediated diseases based on defined
bacterial consortia, today announced that it has been awarded a
second research grant from CARB-X (Combating Antibiotic Resistant
Bacteria Biopharmaceutical Accelerator), a global non-profit
partnership dedicated to accelerating early development in
antibacterial R&D to address the rising global threat of
drug-resistant bacteria, of $5.8 million. In addition to the
initial grant, Vedanta Biosciences is eligible for $3.5 million in
further funding upon completion of specific milestones.
The funding will be directed towards the development of VE707,
Vedanta's preclinical human microbiome-derived discovery programme
designed to restore a healthy microbiota as well as prevent
infection and colonisation recurrence of several multi-drug
resistant organisms (MDRO) that are responsible for hundreds of
thousands of infections in high-risk patients in the United States
and Europe each year.
"The addition of Vedanta's VE707 programme to the CARB-X
portfolio expands the rich diversity of our pipeline and reflects a
novel approach against drug-resistant infections," said Kevin
Outterson, executive director of CARB-X. "Innovations such as
VE707, if successful and approved for use in patients, could offer
physicians broader treatment options that would strengthen a
patient's ability to fight serious infections and limit the spread
of drug-resistant bacteria."
VE707 is designed to prevent MDRO infections that can result in
life-threatening treatment delays and death. These infections
result in approximately $2 billion of additional healthcare costs
relating to patient isolation practices alone.
"We are very pleased to partner with CARB-X for a second time
and look forward to working with the CARB-X team to develop an
alternative to antibiotics to help address the burden of MDRO
infections," said Bernat Olle, PhD, chief executive officer of
Vedanta Biosciences. "If we could get rid of intestinal carriage of
these MDROs in high-risk patients, we could not only prevent
infections, but also curb the transmission of these organisms and
enable physicians to avoid using antibiotics that select for
ever-more resistant bacterial strains."
Vedanta Biosciences received its first grant from CARB-X for
$5.4 million in 2017 to support clinical testing of Vedanta's oral
product candidate, VE303, for the potential treatment of recurrent
Clostridioides difficile infection (rCDI).
About VE707
VE707 is Vedanta's preclinical discovery programme for the
prevention of infection and colonisation recurrence of several
MDROs. VE707 is designed to be administered orally and consists of
a defined consortium of commensal bacteria. It is produced from
pure, clonal bacterial cell banks, which yield a product of uniform
composition and free of any pathogenic strains, bypassing the need
to rely on faecal donor material with inconsistent composition.
VE707 is designed to decolonise gut-dwelling multi-drug resistant
organisms in patients at high-risk for developing infections.
Specifically, VE707 is being developed to eliminate intestinal
carriage of carbapenem-resistant Enterobacteriaceae (CRE),
extended-spectrum beta lactamase producers (ESBL), and
vancomycin-resistant Enterococci (VRE) to restore a healthy
microbiota as well as prevent infection and colonisation
recurrence. CRE, ESBL, and VRE infections are some of the most
common hospital-acquired infections and are estimated to affect
over 500,000 intensive care unit, dialysis, solid organ transplant,
and haematopoietic stem cell transplant patients each year in the
US and Europe. Infections with these organisms can result in
life-threatening treatment delays or death and result in
approximately $2 billion healthcare-associated costs due to patient
isolation practices alone.
About CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical
Accelerator (CARB-X) is a global non-profit partnership dedicated
to accelerating early development antibacterial R&D to address
the rising global threat of drug-resistant bacteria. CARB-X is led
by Boston University and funding is provided by the Biomedical
Advanced Research and Development Authority (BARDA), part of the
Office of the Assistant Secretary for Preparedness and Response
(ASPR) in the US Department of Health and Human Services, the
Wellcome Trust, a global charity based in the UK working to improve
health globally, Germany's Federal Ministry of Education and
Research (BMBF), the Bill & Melinda Gates Foundation, and with
in-kind support from National Institute of Allergy and Infectious
Diseases (NIAID), part of the US National Institutes of Health
(NIH). A non-profit partnership, CARB-X is investing up to $500
million from 2016-2021 to support innovative antibiotics and other
therapeutics, vaccines, and rapid diagnostics. CARB-X supports the
world's largest and most innovative pipeline of preclinical
products against drug-resistant infections. CARB-X is headquartered
at Boston University School of Law. https://carb-x.org/. Follow us
on Twitter @CARB_X.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage microbiome leader
developing a new category of therapies for immune-mediated diseases
based on rationally-defined consortia of human microbiome-derived
non-pathogenic bacteria. Vedanta's proprietary capabilities include
what is believed to be the largest collection of human-gut
associated bacteria, assays and bioinformatics techniques for
consortia design and optimisation, vast datasets from human
interventional studies and facilities for cGMP-compliant
manufacturing of rationally-defined bacterial consortia in powder
form.
Vedanta Biosciences' pioneering work, in collaboration with its
scientific co-founders, has led to the identification of human
commensal bacteria that induce a range of immune responses -
including induction of regulatory T cells, CD8+ T cells, and Th17
cells, among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature (2013,
2019), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of investigational live biotherapeutic products
(LBPs) in infectious disease, autoimmune disease, allergy, and
immuno-oncology. This pipeline includes three clinical-stage
product candidates currently being evaluated for the treatment of
recurrent C. difficile infection and inflammatory bowel disease (in
collaboration with Janssen Biotech, Inc.), and food allergy, as
well as a fourth product candidate expected to enter the clinic in
2019 in patients with advanced or metastatic cancers (in
combination with Bristol-Myers Squibb's checkpoint inhibitor
OPDIVO(R)).
Vedanta's IP portfolio contains over 30 issued patents with
coverage through at least 2031. Vedanta Biosciences was founded by
PureTech Health (LSE: PRTC). Its scientific co-founders are
world-renowned experts in immunology and microbiology who have
pioneered the fields of innate immunity, Th17 and regulatory T cell
biology.
About PureTech Health
PureTech is a clinical stage biotechnology company dedicated to
discovering, developing and commercialising highly differentiated
medicines for devastating diseases, including intractable cancers,
lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's affiliates, is comprised of 24 product
candidates and one product that has been cleared by the US Food and
Drug Administration (FDA). All of the underlying programmes and
platforms that resulted in this pipeline of product candidates were
initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune, and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAFALEESNFAF
(END) Dow Jones Newswires
December 05, 2019 02:01 ET (07:01 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
